The Global Hereditary Angioedema Market, by Drug Class (C1 Esterase Inhibitor, Kallikrein Inhibitor, Bradykinin Receptor, Attenuated Androgens, and Others), By Route of Administration (Subcutaneous, Intravenous, and Oral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and e-Commerce) and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 1,563.7 million in 2016 and is projected to exhibit a CAGR of 9.1% over the forecast period (2017 – 2025).
The hereditary angioedema market is expected to gain significant traction with the rising innovations for the development of novel drugs by the manufacturers and increasing R&D initiatives undertaken by research foundations.
Novel delivery platforms adopted by manufacturers to drive the global market growth
Positive clinical trial results integrated with assured safety profiles to cater the unmet need of the disease are the major factors to augment the global hereditary angioedema market in the foreseeable period. For instance, in 2016, RNAi-based candidate ARC-F12 by Arrowhead Pharmaceuticals is currently in preclinical development and is a potential treatment for factor XII (F12) mediated diseases. The RNAi based candidate is expected to present opportunities in the treatment of hereditary angioedema, thus the Arrowhead is currently conducting studies to advance the candidate into the clinical trials. Furthermore, the novel gene therapy product candidate by Adverum Biotechnologies named AADVM-053 is presently in the preclinical trials for the treatment of patients HAE. ADVM-053 is an Adeno Associated Virus (AAV) based gene transfer vector that aims to provide persistent levels of human C1-esterase inhibitor (C1-INH) to potentially correct the deficiency state that can lead to life-threatening attacks.
Browse 58 Market Data Tables and 32 Figures spread through 175 Pages and in-depth TOC on “Hereditary Angioedema Market”- Global Forecast to 2025.
To know the latest trends and insights prevalent in the hereditary angioedema market, click the link below:
The key players are adopting strategic collaborations and acquisitions for the development and expansion of the HAE portfolio and to accelerate respective pipelines for faster delivery of the products. For instance, In January 2018, BioCryst Pharmaceuticals and Idera Pharmaceuticals merged to create a new rare-disease company. The companies currently have two phase 3 clinical compounds, including BioCryst’s BCX7353 and Idera’s IMO-8400. In 2017, Diplomat Pharmacy, Inc. acquired Focus Rx Pharmacy Services Inc., to offer extensive solutions to meet the growing demand for infusion therapies for individuals living with chronic conditions including hereditary angioedema and other disorders. In 2015, Shire Plc acquired Dyax Corp. with a strategy to get access and achieve worldwide sales of lead pipeline product DX-2930, Phase 3-ready, fully-humanized monoclonal antibody. The FDA granted DX-2930 fast track, breakthrough therapy, and orphan drug designation in the EU.
Key Takeaways of the Hereditary Angioedema Market: